Company AstraZeneca PLC Nasdaq

Company AstraZeneca PLC Nasdaq

AZN

US0463531089

Pharmaceuticals

Analysts' Consensus

Equities

AZN

US0463531089

Pharmaceuticals

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Group companies

Sector

Sales per Business

Sales per region

Ratings for AstraZeneca PLC

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Group companies

Sector

Sales per Business

Sales per region

Ratings for AstraZeneca PLC

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
76.9 ^USD	-0.18%		-0.36%	+14.18%

May. 17	Pfizer wins $107.5 million from AstraZeneca in US cancer drug patent trial	RE
May. 16	AstraZeneca's Sipavibart Prevents COVID-19 in Immunocompromised Patients in Phase 3 Trial	MT

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:

- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);

- collaboration revenue (4.4%).

Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Number of employees: 89,900

GBP in Million	2022	Weight	2023	Weight	Delta
Oncology 37.4 %	11,878	33.0 %	13,793	37.4 %	+16.12%
Cardiovascular, Renal and Metabolism 23.1 %	7,459	20.7 %	8,515	23.1 %	+14.16%
Rare Disease 16.9 %	5,726	15.9 %	6,246	16.9 %	+9.08%
Respiratory and Immunology 13.3 %	4,680	13.0 %	4,913	13.3 %	+4.97%
Alliance 3.1 %	-	-	1,149	3.1 %	-
Other Medicines 2.6 %	1,319	3.7 %	946	2.6 %	-28.29%
Vaccines and Immune Therapies 2.2 %	3,845	10.7 %	814	2.2 %	-78.83%
Collaboration 1.3 %	1,098	3.1 %	478	1.3 %	-56.50%

GBP in Million	2022	Weight	2023	Weight	Delta
United States 39.6 %	14,027	39.0 %	14,578	39.6 %	+3.93%
China 12.8 %	4,662	12.9 %	4,724	12.8 %	+1.32%
Japan 7.9 %	3,236	9.0 %	2,928	7.9 %	-9.51%
United Kingdom 7.4 %	2,530	7.0 %	2,709	7.4 %	+7.07%
Other Rest of Europe 6.8 %	2,197	6.1 %	2,502	6.8 %	+13.89%
Germany 4.6 %	1,544	4.3 %	1,689	4.6 %	+9.36%
Other Asia, Africa and Australasia 4.5 %	1,953	5.4 %	1,645	4.5 %	-15.77%
Sweden 3.7 %	1,397	3.9 %	1,371	3.7 %	-1.89%
Other Americas 3.7 %	954	2.6 %	1,354	3.7 %	+41.94%
France 2.5 %	899	2.5 %	927	2.5 %	+3.12%
Canada 2.1 %	947	2.6 %	778	2.1 %	-17.82%
Spain 1.8 %	599	1.7 %	681	1.8 %	+13.73%
Italy 1.8 %	597	1.7 %	654	1.8 %	+9.61%
Australia 0.9 %	464	1.3 %	314	0.9 %	-32.32%

Managers	Title	Age	Since
Pascal Soriot CEO	Chief Executive Officer	64	12-09-30
Aradhana Sarin DFI	Director of Finance/CFO	50	21-07-31
Cindy Hoots CTO	Chief Tech/Sci/R&D Officer	56	19-12-31
Sharon Barr CTO	Chief Tech/Sci/R&D Officer	-	23-07-31
Regina Danielson CTO	Chief Tech/Sci/R&D Officer	60	-
Alberto Hegewisch CTO	Chief Tech/Sci/R&D Officer	-	23-05-17
Pam Cheng COO	Chief Operating Officer	53	15-05-31
Jeffrey Pott CMP	Compliance Officer	-	94-12-31
Margareta Elisabeth Björk PRN	Corporate Officer/Principal	63	01-12-31
Iskra Reic PRN	Corporate Officer/Principal	-	00-12-31

Members of the board	Title	Age	Since
Sherilyn McCoy BRD	Director/Board Member	65	17-09-30
Ahmed Hamdy PRN	Corporate Officer/Principal	59	13-01-31
Philip Broadley BRD	Director/Board Member	63	17-04-26
Marcus Wallenberg BRD	Director/Board Member	68	99-03-31
Marc Dunoyer PRN	Corporate Officer/Principal	71	13-05-31
Andreas Rummelt BRD	Director/Board Member	66	21-07-31
Michel Demaré CHM	Chairman	67	19-08-31
Pascal Soriot CEO	Chief Executive Officer	64	12-09-30
Deborah DiSanzo BRD	Director/Board Member	64	17-11-30
Aradhana Sarin DFI	Director of Finance/CFO	50	21-07-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	1,550,235,025	1,497,890,686 ( 96.62 %)	0	96.62 %

Name	Equities	%	Valuation
BlackRock Investment Management (UK) Ltd. 4.420 %	68,512,693	4.420 %	10 348 M $
Wellington Management Co. LLP 4.201 %	65,120,892	4.201 %	9 835 M $
The Vanguard Group, Inc. 3.593 %	55,698,000	3.593 %	8 412 M $
Investor AB (Investment Company) 3.328 %	51,587,810	3.328 %	7 792 M $
Norges Bank Investment Management 2.216 %	34,357,000	2.216 %	5 189 M $
BlackRock Fund Advisors 1.918 %	29,736,171	1.918 %	4 491 M $
BlackRock Advisors (UK) Ltd. 1.418 %	21,987,529	1.418 %	3 321 M $
Legal & General Investment Management Ltd. 0.9998 %	15,499,242	0.9998 %	2 341 M $
BlackRock Advisors LLC 0.9901 %	15,349,305	0.9901 %	2 318 M $
SSgA Funds Management, Inc. 0.9826 %	15,233,000	0.9826 %	2 301 M $

Name	Equities	%	Valuation
T. Rowe Price International Ltd. 1.976 %	61,271,974	1.976 %	4 597 M $
Wellington Management Co. LLP 1.584 %	49,121,861	1.584 %	3 686 M $
PRIMECAP Management Co. 1.385 %	42,945,175	1.385 %	3 222 M $
Capital Research & Management Co. (International Investors) 1.113 %	34,521,875	1.113 %	2 590 M $
Fidelity Management & Research Co. LLC 0.6678 %	20,704,467	0.6678 %	1 553 M $
Jennison Associates LLC 0.5572 %	17,276,282	0.5572 %	1 296 M $
Fiduciary Trust Company International 0.5555 %	17,222,116	0.5555 %	1 292 M $
Eaton Vance Management 0.4871 %	15,101,147	0.4871 %	1 133 M $
Sanders Capital LLC 0.4780 %	14,818,983	0.4780 %	1 112 M $
The Ayco Co. LP 0.3982 %	12,346,115	0.3982 %	926 M $

Name	Equities	%	Valuation
Caixa DTVM SA 0.003077 %	286,303	0.003077 %	4 M $

Name	Equities	%	Valuation
ASTRAZENECA PHARMA INDIA LIMITED 75.00%	18,750,000	75.00%	1,200,298,875 $
SWEDISH ORPHAN BIOVITRUM AB 9.06%	32,100,518	9.06%	834,691,151 $
DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. 37.58%	108,923,023	37.58%	677,619,929 $
NIOX GROUP PLC 16.81%	71,065,878	16.81%	63,179,698 $
CELLECTIS S.A. 22.30%	16,000,000	22.30%	41,657,920 $
INNATE PHARMA 9.26%	7,485,500	9.26%	17,648,563 $
PIERIS PHARMACEUTICALS, INC. 3.62%	44,803	3.62%	519,715 $
ARIDIS PHARMACEUTICALS, INC. 1.99%	884,956	1.99%	57,522 $

AstraZeneca PLC

Cambridge Biomedical Campus 1 Francis Crick Avenue

CB2 0AA, Cambridge

+44 20 3749 5000

http://www.astrazeneca.co.uk

Name	Category and Sector
R&Q Beta Co. Plc R&Q Beta Co. Plc Insurance Brokers/ServicesFinance R&Q Beta Co. Plc provides insurance services. The company was founded in 1994 and is headquartered in Cambridge, the United Kingdom.	Insurance Brokers/Services
AstraZeneca AB AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden.	Miscellaneous Commercial Services
Alexion Pharmaceuticals, Inc. /New/
Astrazeneca Finance & Holdings, Inc. Astrazeneca Finance & Holdings, Inc. Financial ConglomeratesFinance Part of AstraZeneca PLC, Astrazeneca Finance & Holdings, Inc. is an investment holding American company. The company is located in the US.	Financial Conglomerates
AstraZeneca India Pvt Ltd. AstraZeneca India Pvt Ltd. Pharmaceuticals: MajorHealth Technology AstraZeneca India Pvt Ltd. operates as a biopharmaceutical company. The company was founded in 1979 and is headquartered in Bangalore, India.	Pharmaceuticals: Major
Astrazeneca Treasury Ltd. Astrazeneca Treasury Ltd. Financial ConglomeratesFinance Part of AstraZeneca PLC, AstraZeneca Treasury Ltd. functions as an investment holding British company. The company is based in Cambridge, UK.	Financial Conglomerates
Astrazeneca Holdings BV
Astrazeneca Treasury BV
AstraZeneca Employee Share Trust Ltd. AstraZeneca Employee Share Trust Ltd. Miscellaneous Commercial ServicesCommercial Services Part of AstraZeneca PLC, AstraZeneca Employee Share Trust Ltd. is a British company that provides business support services. The company is located in the UK.	Miscellaneous Commercial Services
AstraZeneca UK Ltd. AstraZeneca UK Ltd. Miscellaneous Commercial ServicesCommercial Services AstraZeneca UK Ltd. manufactures pharmaceutical products. Its products are used to treat cardiovascular diseases, diabetes, and gastrointestinal infections. The company was founded on November 26, 1998 and is headquartered in London, the United Kingdom.	Miscellaneous Commercial Services
AstraZeneca Share Trust Ltd. AstraZeneca Share Trust Ltd. Miscellaneous Commercial ServicesCommercial Services Part of AstraZeneca PLC, AstraZeneca Share Trust Ltd. is a British company that provides business support services. The company is located in the UK.	Miscellaneous Commercial Services
AstraZeneca Finance LLC	Finance/Rental/Leasing
ASTRAZENECA PHARMA INDIA LIMITED	Pharmaceuticals: Major

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

153.9 USD

Average target price

167.6 USD

Spread / Average Target

+8.90%

Consensus

Estimates Revisions

Company calendar

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+32.09%	693B
NOVO NORDISK A/S	+29.39%	584B
JOHNSON & JOHNSON	-1.34%	372B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+7.39%	294B
ROCHE HOLDING AG	-3.03%	211B
NOVARTIS AG	+10.02%	210B
AMGEN INC.	+8.49%	168B
PFIZER, INC.	-0.52%	162B

Other Pharmaceuticals

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals